Nuevolution maintains guidance despite million-dollar loss
Sales stood still during the first half of Nuevolution’s staggered financial year. It resulted in a loss of DKK 46 million. However, the CEO assures that the company is still going strong. “That’s biotech,” he says.
BY KEVIN GRØNNEMANN
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.